Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Kidney (Renal Cell)

This is a Phase 1b / 2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone
Kidney (Renal Cell)
I/II
Beckermann, Kathryn
NCT04300140
VICCUROP2016

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: